Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467
Discontinued
Reference number: GID-TA10353
The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of elotuzumab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma ID1467. We have recently invited stakeholders to respond to a written consultation on the draft scope.
The company that is developing elotuzumab have shared confidential information with NICE. In light of this information the Institute will not be progressing with the scoping exercise. Consequently the consultation on the draft scope will be closed early. The topic will still progress to Technology Appraisal stage
If you have any comments or concerns please contact the project manager for this appraisal Michelle Adhemar at michelle.adhemar@nice.org.uk